Analyst Soumit Roy from JonesTrading maintained a Buy rating on Day One Biopharmaceuticals (DAWN – Research Report) and decreased the price target to $26.00 from $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Soumit Roy has given his Buy rating due to a combination of factors that highlight Day One Biopharmaceuticals’ potential for growth. Despite a slight dip in first-quarter revenue, attributed to seasonal factors, the company is expected to see consistent growth with its drug Ojemda throughout 2025. As the drug gains more acceptance among conservative doctors, its penetration in the market is anticipated to improve.
Additionally, the company’s strong cash position of $473 million, coupled with its best-in-class commercial product and experienced management team, presents a compelling buying opportunity. The stock is currently at its lowest valuation in over 30 months, making it an attractive investment with a holding period of at least 12 months. Furthermore, the ongoing development of their pipeline, including the ‘301 project, could provide significant value inflection points in the future.
In another report released today, Needham also maintained a Buy rating on the stock with a $27.00 price target.